UGCG is Involved in Oxaliplatin Resistance Mechanism of Human Colon Cancer Through Regulating MDR1/P-gp Expression
-
摘要:目的
建立人结肠癌耐奥沙利铂（L-OHP）细胞株，检测该细胞株的多药耐药性并初步探讨其可能的耐药机制。
方法以人结肠癌细胞HCT116为对象，采用药物浓度梯度递增诱导法建立人结肠癌耐奥沙利铂细胞株HCT-116/L-OHP。CCK-8法检测L-OHP、顺铂（DDP）、5-氟尿嘧啶（5-Fu）对亲本细胞和耐药细胞株的半数抑制浓度（IC50）。使用UDP-葡萄糖神经酰胺糖基转移酶（UGCG）siRNA转染HCT-116/L-OHP细胞，实时荧光定量 PCR和Western blot检测干扰前后UGCG基因和多药耐药基因1（MDR1）mRNA及其编码的蛋白表达水平。
结果HCT-116/L-OHP对L-OHP的耐药指数为10.5，与DDP有一定程度的交叉耐药，耐药指数为4.61，但对5-Fu无交叉耐药。耐药细胞HCT-116/L-OHP中UGCG、MDR1 mRNA和UGCG、P-糖蛋白（P-gp, MDR1编码的蛋白）表达均增加，相比HCT-116细胞，差异具有统计学意义（P<0.05）。UGCG siRNA成功抑制HCT-116/L-OHP细胞中UGCG的表达，各干扰组MDR1 mRNA、P-gp表达减少，与对照组相比差异具有统计学意义（P<0.05）。
结论成功构建了人结肠癌耐药细胞株；UGCG基因通过调控MDR1/P-gp的表达参与人结肠癌奥沙利铂的耐药机制的形成。
-
关键词:
- 奥沙利铂 /
- 多药耐药 /
- UDP-葡萄糖神经酰胺糖基转移酶 /
- P-糖蛋白
Abstract:ObjectiveTo establish and authenticate an oxaliplatin (L-OHP) resistant human colon cancer cell line, and to preliminarily explore the multidrug resistance mechanism.
MethodsAn L-OHP-resistant human colon cancer cell line, HCT116/L-OHP, was established by gradually increasing the dose of L-OHP in the culture. The half inhibition concentration (IC50) of L-OHP, cisplatin (DDP) and 5-fluorouracil (5-Fu) in HCT116 and HCT116/L-OHP cell lines were evaluated by CCK8 assay. The siRNAs of UDP-glucose ceramide glucosyltransferase (UGCG) were used to transfect HCT-116/L-OHP cells. The gene and protein expression levels of UGCG and multidrug resistance gene1 (MDR1) were examined by real-time reverse transcription-polymerase chain reaction(PCR) and Western blot.
ResultsThe resistance index to L-OHP in HCT116/L-OHP cell line was 10.5. In addition, HCT116/L-OHP cell line had cross resistance with DDP by 4.61 of the resistance index, but not with 5-Fu. The expression levels of UGCG mRNA, MDR1 mRNA, UGCG protein and P-glycoprotein (P-gp, encoded by MDR1 gene) were significantly higher in HCT116/L-OHP cells than those in HCT116 cells (P<0.05). After transfected with UGCG siRNA, both UGCG gene and protein expression were inhibited in HCT116/L-OHP cells. Compared with the negative control, the expression of MDR1 mRNA and P-gp were also significantly decreased (P<0.05).
ConclusionL-OHP resistant human colorectal cancer cell line HCT116/L-OHP are successfully established, and UGCG is involved in L-OHP resistance mechanism of human colon cancer through regulating MDR1/P-gp expression.
-
Key words:
- L-OHP /
- Multidrug resistance /
- UGCG /
- P-gp
-
-
![]()
图 1 不同浓度L-OHP、DDP和5-Fu对HCT116、HCT116/L-OHP细胞的生长抑制作用
Figure 1 Inhibitory effect of different concentrations of L-OHP,DDP and 5-Fu on HCT116 and HCT116/L-OHP cells
![]()
图 2 HCT116和HCT116/L-OHP中UGCG和MDR1 mRNA表达水平
Figure 2 Expression of UGCG and MDR1 mRNA in HCT116 and HCT116/L-OHP cells
![]()
图 3 HCT116和HCT116/L-OHP细胞中UGCG、P-gp蛋白的表达
Figure 3 Expression of UGCG and P-gp protein in HCT116 and HCT116/L-OHP cells
![]()
图 4 UGCG siRNA转染后HCT116/L-OHP细胞中UGCG和MDR1 mRNA的表达
Figure 4 Expression of UGCG and MDR1 mRNA in HCT116/L-OHP cells after UGCG siRNA transfection
![]()
图 5 UGCG siRNA转染后HCT116/L-OHP细胞中UGCG、P-gp蛋白的表达
Figure 5 Expression of UGCG and P-gp protein in HCT116/L-OHP after UGCG siRNA transfection
-
[1] Raymond E, Chaney SG, Taamma A, et al. Oxaliplatin: a review of preclinical and clinical studies[J]. Ann Oncol, 1998, 9(10): 1053-71. doi: 10.1023/A:1008213732429
[1] Raymond E, Chaney SG, Taamma A, et al. Oxaliplatin: a review of preclinical and clinical studies[J]. Ann Oncol, 1998, 9(10): 10 53-71. [2] Patwardhan G, Gupta V, Huang J, et al. Direct assessment of P-glycoprotein efflux to determine tumor response to chemotherapy[J]. Biochem Pharmacol, 2010, 80(1): 72-9. [2] Patwardhan G, Gupta V, Huang J, et al. Direct assessment of P-glycoprotein efflux to determine tumor response to chemotherapy[J]. Biochem Pharmacol, 2010, 80(1): 72-9. doi: 10.1016/j.bcp.2010.03.010
[3] 张秀芬, 谢可鸣, 邹健, 等. NS-κB介导白血病多药耐药细胞中葡萄糖神经酰胺合成酶对P-糖蛋白的调节作用[J]. 中华医学遗传学杂志, 2014, 31(1): 34-8. http://cdmd.cnki.com.cn/article/cdmd-10285-1013242707.htm Zhang XF, Xie KM, Zou J, et al. NF-κB the effect of glucosylceramide synthase on P-glycoprotein modulation in a drug-resistance leukemia cell line[J]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi, 2014, 31(1): 34-8. http://cdmd.cnki.com.cn/article/cdmd-10285-1013242707.htm
[3] 张秀芬, 谢可鸣, 邹健, 等. NS-κB介导白血病多药耐药细胞中 葡萄糖神经酰胺合成酶对P-糖蛋白的调节作用[J]. 中华医学 遗传学杂志, 2014, 31(1): 34-8. [Zhang XF, Xie KM, Zou J, et al. NF-κB the effect of glucosylceramide synthase on P-glycoprotein modulation in a drug-resistance leukemia cell line[J]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi, 2014, 31(1): 34-8.] [4] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015[J]. CA Cancer J Clin, 2015, 65(1): 5-29. doi: 10.3322/caac.21254
[4] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015[J]. CA Cancer J Clin, 2015, 65(1): 5-29. [5] Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 20 12[J]. CA Cancer J Clin, 2015, 65(2): 87-108. [5] Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012[J]. CA Cancer J Clin, 2015, 65(2): 87-108. doi: 10.3322/caac.21262
[6] Szakacs G, Paterson JK, Ludwig JA, et al. Targeting multidrug resistance in cancer[J]. Nat Rev Drug Discov, 2006, 5(3): 219-34. doi: 10.1038/nrd1984
[6] Szakacs G, Paterson JK, Ludwig JA, et al. Targeting multidrug resistance in cancer[J]. Nat Rev Drug Discov, 2006, 5(3): 219-34. [7] Wilson TR, Johnston PG, Longley DB. Anti-apoptotic mechanisms of drug resistance in cancer[J]. Curr Cancer Drug Targets, 2009, 9(3): 307-19. doi: 10.2174/156800909788166547
[7] Wilson TR, Johnston PG, Longley DB. Anti-apoptotic mechanisms of drug resistance in cancer[J]. Curr Cancer Drug Targets, 2009, 9(3): 307-19. [8] Dallas NA, Xia L, Fan F, et al. Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition[J]. Cancer Res, 20 09, 69(5): 1951-7. [8] Dallas NA, Xia L, Fan F, et al. Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition[J]. Cancer Res, 2009, 69(5): 1951-7. doi: 10.1158/0008-5472.CAN-08-2023
[9] Dimanche-Boitrel MT, Rebillard A, Gulbins E. Ceramide in chemotherapy of tumors[J]. Recent Pat Anticancer Drug Discov, 2011, 6(3): 284-93. doi: 10.2174/157489211796957838
[9] Dimanche-Boitrel MT, Rebillard A, Gulbins E. Ceramide in chemotherapy of tumors[J]. Recent Pat Anticancer Drug Discov, 20 11, 6(3): 284-93. [10] Dumitru CA, Weller M, Gulbins E. Ceramide metabolism determines glioma cell resistance to chemotherapy[J]. J Cell Physiol, 2009, 221(3): 688-95. [10] Dumitru CA, Weller M, Gulbins E. Ceramide metabolism determines glioma cell resistance to chemotherapy[J]. J Cell Physiol, 2009, 221(3): 688-95. doi: 10.1002/jcp.21907
[11] Liu YY, Yu JY, Yin D, et al. A role for ceramide in driving cancer cell resistance to doxorubicin[J]. FASEB J, 2008, 22(7): 2541-51. doi: 10.1096/fj.07-092981
[11] Liu YY, Yu JY, Yin D, et al. A role for ceramide in driving cancer cell resistance to doxorubicin[J]. FASEB J, 2008, 22(7): 2541-51. [12] Wu CP, Calcagno AM, Ambudkar SV. Reversal of ABC drug transporter-mediated multidrug resistance in cancer cells: evaluation of current strategies[J]. Curr Mol Pharmacol, 2008, 1( 2): 93-105. [12] Wu CP, Calcagno AM, Ambudkar SV. Reversal of ABC drug transporter-mediated multidrug resistance in cancer cells: evaluation of current strategies[J]. Curr Mol Pharmacol, 2008, 1(2): 93-105. doi: 10.2174/1874467210801020093
[13] Cole SP. Targeting multidrug resistance protein 1 (MRP1, ABCC1): past, present, and future[J]. Annu Rev Pharmacol Toxicol, 2014, 54: 95-117. [13] Cole SP. Targeting multidrug resistance protein 1 (MRP1, ABCC1): past, present, and future[J]. Annu Rev Pharmacol Toxicol, 2014, 54: 95-117. doi: 10.1146/annurev-pharmtox-011613-135959
[14] Aldonza MB, Hong JY, Bae SY, et al. Suppression of MAPK Signaling and Reversal of mTOR-Dependent MDR1-Associated Multidrug Resistance by 21α-Methylmelianodiol in Lung Cancer Cells[J]. PLoS One, 2015, 10(6): e0127841. doi: 10.1371/journal.pone.0127841
[14] Aldonza MB, Hong JY, Bae SY, et al. Suppression of MAPK Signaling and Reversal of mTOR-Dependent MDR1-Associated Multidrug Resistance by 21α-Methylmelianodiol in Lung Cancer Cells[J]. PLoS One, 2015, 10(6): e0127841. [15] 许月天, 孙剑经. NS-398逆转结肠癌细胞多药耐药性的作用 [J] 肿瘤防治研究, 2015, 42(9): 877-81. [Xu YT, Sun JJ. NS-398 Reverses Multi-drug Resistance of Colorectal Carcinoma Cells[J]. Zhong Liu Fang Zhi Yan Jiu, 2015, 42(9): 877-81.] [15] 许月天, 孙剑经. NS-398逆转结肠癌细胞多药耐药性的作用[J]. 肿瘤防治研究, 2015, 42(9): 877-81. http://www.zlfzyj.com/CN/abstract/abstract8582.shtml Xu YT, Sun JJ. NS-398 Reverses Multi-drug Resistance of Colorectal Carcinoma Cells[J]. Zhong Liu Fang Zhi Yan Jiu, 2015, 42(9): 877-81. http://www.zlfzyj.com/CN/abstract/abstract8582.shtml
[16] Noratto GD, Jutooru I, Safe S, et al. The drug resistance suppression induced by curcuminoids in colon cancer SW-480 cells is mediated by reactive oxygen species-induced disruption of the microRNA-27a-ZBTB10-Sp axis[J]. Mol Nutr Food Res, 20 13, 57(9): 1638-48. [16] Noratto GD, Jutooru I, Safe S, et al. The drug resistance suppression induced by curcuminoids in colon cancer SW-480 cells is mediated by reactive oxygen species-induced disruption of the microRNA-27a-ZBTB10-Sp axis[J]. Mol Nutr Food Res, 2013, 57(9): 1638-48. doi: 10.1002/mnfr.v57.9
[17] Zhao Q, Li Y, Tan BB, et al. HIF-1α Induces Multidrug Resistance in Gastric Cancer Cells by Inducing MiR-27a[J]. PLoS One, 2015, 10(8): e0132746. doi: 10.1371/journal.pone.0132746
[17] Zhao Q, Li Y, Tan BB, et al. HIF-1α Induces Multidrug Resistance in Gastric Cancer Cells by Inducing MiR-27a[J]. PLoS One, 2015, 10 (8): e0132746.
下载:
计量
- 文章访问数: 1666
- HTML全文浏览量: 315
- PDF下载量: 532
